Literature DB >> 8470266

Atherosclerosis: current understanding of mechanisms and future strategies in therapy.

R Ross1.   

Abstract

The lesions of atherosclerosis represent a protective, inflammatory-fibroproliferative response against the different agents that can cause the disease. If the injury continues chronically over a sufficiently long period of time, and if opportunity is not given for restitution of normal architecture in the artery wall, lesions may progress to a point at which clinical sequelae develop. On the other hand, as demonstrated by Brown et al, Kane et al, and Blankenhorn et al, the advanced lesions of atherosclerosis can be shown to regress. A quantitative, statistical analysis of angiograms in patients who are aggressively treated with lipid-lowering agents, such as HMGCoA reductase inhibitors has clearly shown this to be the case. Thus, it is entirely conceivable that this chronic, excessive, inflammatory, and fibroproliferative response can be reversed, given sufficient opportunity for the factors that have led to the endothelial and arterial wall injury causing these events to be taken into hand and modified.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8470266

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  15 in total

1.  Genomic rearrangements on VCAM1, SELE, APEG1and AIF1 loci in atherosclerosis.

Authors:  D A Arvanitis; G A Flouris; D A Spandidos
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

Review 2.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

3.  Isolation of endothelial cells and vascular smooth muscle cells from internal mammary artery tissue.

Authors:  Stephanie C Moss; Michael Bates; Patrick E Parrino; T Cooper Woods
Journal:  Ochsner J       Date:  2007

Review 4.  Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease.

Authors:  Gregory A Payne; Meredith C Kohr; Johnathan D Tune
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  In vivo interrogation of the molecular display of atherosclerotic lesion surfaces.

Authors:  Cheng Liu; Gourab Bhattacharjee; William Boisvert; Ralph Dilley; Thomas Edgington
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

6.  Identification and characterization of Chlamydia pneumoniae-specific proteins that activate tumor necrosis factor alpha production in RAW 264.7 murine macrophages.

Authors:  Shinn-Jong Jiang; Cho-Chou Kuo; Mark W Berry; Amy W Lee; Lee Ann Campbell
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

7.  Astragalus polysaccharides suppress ICAM-1 and VCAM-1 expression in TNF-α-treated human vascular endothelial cells by blocking NF-κB activation.

Authors:  Yu-ping Zhu; Tao Shen; Ya-jun Lin; Bei-dong Chen; Yang Ruan; Yuan Cao; Yue Qiao; Yong Man; Shu Wang; Jian Li
Journal:  Acta Pharmacol Sin       Date:  2013-06-03       Impact factor: 6.150

8.  Pro-atherogenic role of smooth muscle Nox4-based NADPH oxidase.

Authors:  Xiaoyong Tong; Alok R Khandelwal; Xiaojuan Wu; Zaicheng Xu; Weimin Yu; Caiyu Chen; Wanzhou Zhao; Jian Yang; Zhexue Qin; Robert M Weisbrod; Francesca Seta; Tetsuro Ago; Kin Sing Stephen Lee; Bruce D Hammock; Junichi Sadoshima; Richard A Cohen; Chunyu Zeng
Journal:  J Mol Cell Cardiol       Date:  2016-01-23       Impact factor: 5.000

9.  Modification of alternative messenger RNA splicing of fibroblast growth factor receptors in human cardiac allografts during rejection.

Authors:  X M Zhao; W H Frist; T K Yeoh; G G Miller
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

10.  A novel anti-inflammatory natural product from Sphaeranthus indicus inhibits expression of VCAM1 and ICAM1, and slows atherosclerosis progression independent of lipid changes.

Authors:  Rai Ajit K Srivastava; Sapna Mistry; Somesh Sharma
Journal:  Nutr Metab (Lond)       Date:  2015-06-05       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.